However, both AML and MDS are heterogeneous diseases, and DLX5 methylation pattern were not analyzed in single tumor cell population such as CD34+ cell population, leading to a huge difference of DLX5 methylation in patients with AML and MDS. This evidence concerns the gene CD34 and acute myeloid leukemia.